This listing of the claims will replace all prior versions and listings of the claims in this application.

In the Claims:

1. A compound of formula:



I,

or a pharmaceutically acceptable salt thereof, wherein

R^1 is selected from the group

H,

C_{1-10} alkyl,

C_{1-10} alkyl substituted by up to three groups selected from aryl, cycloalkyl, heteroaryl, heterocycle, $NR^{10}R^{11}$, OR^{12}, SR^{12}, halogen, COR^{13}, CO_2R^{13}, $CONR^{13}R^{14}$, $SO_2NR^{13}R^{14}$, SOR^{13}, SO_2R^{13}, CN and NO_2, wherein the aryl, cycloalkyl, heteroaryl, and heterocycle groups may each independently be substituted by up to three groups selected from $NR^{10}R^{11}$, OR^{12}, SR^{12}, , halogen, COR^{13}, CO_2R^{13}, $CONR^{13}R^{14}$, $SO_2NR^{13}R^{14}$, SOR^{13}, SO_2R^{13}, CN and NO_2,

aryl,

aryl substituted by up to three groups selected from lower alkyl, $NR^{10}R^{11}$, OR^{12}, SR^{12}, , halogen, COR^{13}, CO_2R^{13}, $CONR^{13}R^{14}$, $SO_2NR^{13}R^{14}$, SOR^{13}, SO_2R^{13}, CN and NO_2,

heteroaryl,

heteroaryl substituted by up to three groups selected from lower alkyl, $NR^{10}R^{11}$, , OR^{12}, SR^{12}, halogen, COR^{13}, CO_2R^{13}, $CONR^{13}R^{14}$, $SO_2NR^{13}R^{14}$, SOR^{13}, SO_2R^{13}, CN and NO_2,

heterocycle,

heterocycle substituted by up to three groups selected from lower alkyl, $NR^{10}R^{11}$, OR^{12}, SR^{12}, halogen, COR^{13}, CO_2R^{13}, $CONR^{13}R^{14}$, $SO_2NR^{13}R^{14}$, SOR^{13}, SO_2R^{13}, CN and NO_2,

C_{3-10} cycloalkyl,

C_{3-10} cycloalkyl substituted by up to three groups selected from lower alkyl $NR^{10}R^{11}$, OR^{12}, SR^{12}, halogen, COR^{13}, CO_2R^{13}, $CONR^{13}R^{14}$, $SO_2NR^{13}R^{14}$, SOR^{13}, SO_2R^{13}, CN and NO_2,

C_{2-10} alkenyl,

C_{2-10} alkenyl substituted by up to three groups selected from $NR^{10}R^{11}$, OR^{12}, SR^{12}, halogen, COR^{13}, CO_2R^{13}, $CONR^{13}R^{14}$, $SO_2NR^{13}R^{14}$, SOR^{13}, SO_2R^{13}, CN and NO_2, and

C_{2-10} alkynyl, substituted by up to three groups selected from $NR^{10}R^{11}$, OR^{12}, SR^{12}, halogen, COR^{13}, CO_2R^{13}, $CONR^{13}R^{14}$, $SO_2NR^{13}R^{14}$, SOR^{13}, SO_2R^{13}, CN and NO_2;

R^2, R^3 and R^4 are independently selected from the group consisting of

H,

$NR^{10}R^{11}$,

OR^{12},

SR^{12},

C_{1-10} alkyl,

C_{1-10} alkyl substituted by up to three groups selected from cycloalkyl, heteroaryl, heterocycle, $NR^{10}R^{11}$, OR^{12}, SR^{12}, halogen, COR^{13}, CO_2R^{13}, $CONR^{13}R^{14}$, $SO_2NR^{13}R^{14}$, SOR^{13}, SO_2R^{13}, CN and NO_2; and wherein the cycloalkyl, heteroaryl, and heterocycle groups may each independently be substituted by up to three groups selected from lower alkyl, $NR^{10}R^{11}$, OR^{12}, SR^{12}, halogen, COR^{113}, CO_2R^{13}, $CONR^{13}R^{14}$, $SO_2NR^{13}R^{14}$, SOR^{13}, SO_2R^{13}, CN and NO_2,

heteroaryl, heteroaryl substituted by up to three groups selected from lower alkyl, $NR^{10}R^{11}$, OR^{12}, SR^{12}, halogen, COR^{13}, CO_2R^{13}, $CONR^{13}R^{14}$, $SO_2NR^{13}R^{14}$, SOR^{13}, SO_2R^{13}, CN and NO_2,

heterocycle, substituted by up to three groups selected from lower alkyl, $NR^{10}R^{11}$, OR^{12}, SR^{12} , halogen, COR^{13}, CO_2R^{13}, $CONR^{13}R^{14}$, $SO_2NR^{13}R^{14}$, SOR^{13}, SO_2R^{13}, CN and NO_2,

C_{3-10} cycloalkyl,

C_{3-10} cycloalkyl substituted by up to three groups selected from lower alkyl, $NR^{10}R^{11}$, OR^{12}, SR^{12} , halogen, COR^{13}, CO_2R^{13}, $CONR^{13}R^{14}$, $SO_2NR^{13}R^{14}$, SOR^{13}, SO_2R^{13}, CN and NO_2,

C_{2-10} alkenyl,

C_{2-10} alkenyl substituted by up to three groups selected from $NR^{10}R^{11}$, OR^{12}, SR^{12}, halogen, COR^{13}, CO_2R^{13}, $CONR^{13}R^{14}$, $SO_2NR^{13}R^{14}$, SOR^{13}, SO_2R^{13}, CN and NO_2,

C_{2-10} alkynyl, and

C_{2-10} alkynyl substituted by up to three groups selected from $NR^{10}R^{11}$, OR^{12}, SR^{12}, halogen, COR^{13}, CO_2R^{13}, $CONR^{13}R^{14}$, $SO_2NR^{13}R^{14}$, SOR^{13}, SO_2R^{13}, CN and NO_2,

Provided that at least one of R^2, R^3 or R^4 is not H.

R^5, R^6, R^7 and R^8 are independently selected from the group

H,

lower alkyl,

lower alkyl substituted by hydroxy or alkoxy,

$NR^{15}R^{16}$,

OH,

OR^{17},

SR^{17},

halogen,

COR^{17},

CO_2R^{17},

$CONR^{17}R^{18}$,

$SO_2NR^{17}R^{18}$,

SOR^{17},

SO_2R^{17}, and

CN;

R^9 is selected from the group

H,



, and

COR^{17};

R^{10} and R^{11} are independently selected from the group

H,

COR^{13},

CO_2R^{13},

$CONR^{13}R^{14}$,

SO_2R^{13},

$SO_2NR^{13}R^{14}$,

lower alkyl,

lower alkyl substituted by hydroxy, alkoxy or $NR^{15}R^{16}$,

cycloalkyl,

cycloalkyl substituted by hydroxy, alkoxy, lower alkyl, or $NR^{15}R^{16}$,
heterocycle, and
heterocycle substituted by hydroxy, alkoxy, lower alkyl, or $NR^{15}R^{16}$,

or, alternatively, $NR^{10}R^{11}$ can form a ring having 3 to 7 atoms, said ring optionally including one or more additional hetero atoms and being optionally substituted by the group consisting of one or more lower alkyl, OR^{12}, COR^{13}, CO_2R^{13}, $CONR^{13}R^{14}$, SOR^{13}, SO_2R^{13}, and $SO_2NR^{13}R^{14}$;

R^{12} is selected from the group
H,
lower alkyl,
COR^{13},
$CONR^{13}R^{14}$,
C_{2-6} alkyl substituted by hydroxy, alkoxy, or $NR^{15}R^{16}$, cycloalkyl,
cycloakyl substituted by hydroxy, alkoxy, lower alkyl, or $NR^{15}R^{16}$,
heterocycle, and
heterocycle substituted by hydroxy, alkoxy, lower alkyl, or $NR^{15}R^{16}$;

R^{13} and R^{14} are independently selected from the group
H,
lower alkyl,
C_{2-6} alkyl substituted by hydroxy, alkoxy, or $NR^{15}R^{16}$,
cycloalkyl,
cycloaklyl substituted by hydroxy, alkoxy, lower alkyl, or $NR^{15}R^{16}$,
heterocycle, and
heterocycle substituted by hydroxy, alkoxy, lower alkyl, or $NR^{15}R^{16}$,

or , alternatively, $NR^{13}R^{14}$ can form a ring having 3 to 7 atoms, said ring optionally including one or more additional hetero atoms and being optionally

substituted by the group consisting of one or more lower alkyl, OR^{17}, COR^{17}, CO_2R^{17}, $CONR^{17}R^{18}$, SO_2R^{17}, and $SO_2NR^{17}R^{18}$;

R^{15} is selected from the group

H,

lower alkyl,

COR^{17}, and

CO_2R^{17}; and

R^{16}, R^{17} and R^{18} are independently selected from the group

H, and

lower alkyl,

or, alternatively, $NR^{15}R^{16}$ and $NR^{17}R^{18}$ can each independently form a ring having 3 to 7 atoms, said ring optionally including one or more additional hetero atoms;

R^{19} and R^{20} are independently selected from the group

H, and

lower alkyl; and

R^{21} is selected from

lower alkyl, and

C_{2-6} alkyl substituted by hydroxy, alkoxy or $NR^{15}R^{16}$,

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 wherein R^1 is selected from aryl and aryl substituted by CN and $CONR^{13}R^{14}$.

3. The compound of claim 1 wherein R^1 is selected from lower alkyl.

4. The compound of claim 2 wherein R^2 is C_{1-10} alkyl substituted by OR^{12} or $NR^{10}R^{11}$.

5. The compound of claim 3 wherein R^2 is OR^{12}.

6. The compound of claim 1 wherein R^3 is H.

7. The compound of claim 1 wherein R^3 and R^4 are H.

8. The compound of claim 1 wherein R^4 is C_{1-10} alkyl substituted by $NR^{10}R^{11}$.

9. The compound of claim 1 wherein R^5 is halogen.

10. The compound of claim 1 having the formula



Ia.

11. A compound selected from the group:

(±)-3-[7-[3-(2-Hydroxy-ethyl)-phenylamino]-3-(4-methoxy-phenyl)-4-methyl-2-oxo-3,4-dihydro-2H-pyrimido[4,5-d]pyrimidin-1-yl]-benzonitrile ;

(±)-3-[7-[3-(2-Diethylamino-ethyl)-phenylamino]-3-(4-methoxy-phenyl)-4-methyl-2-oxo-3,4-dihydro-2H-pyrimido[4,5-d]pyrimidin-1-yl]-benzonitrile ; and

(±)-3-[7-[3-(2-Dimethylamino-ethyl)-phenylamino]-3-(4-methoxy-phenyl)-4-methyl-2-oxo-3,4-dihydro-2H-pyrimido[4,5-d]pyrimidin-1-yl]-benzonitrile .

12. A compound selected from the group:

(±)-3-(3-(4-Methoxy-phenyl)-4-methyl-7-{3-[2-(4-methyl-piperazin-1-yl)-ethyl]-phenylamino}-2-oxo-3,4-dihydro-2H-pyrimido[4,5-d]pyrimidin-1-yl)-benzonitrile ;

(±)-3-[7-[3-(2-Diethylamino-ethyl)-phenylamino]-3-(4-methoxy-phenyl)-4-methyl-2-oxo-3,4-dihydro-2H-pyrimido[4,5-d]pyrimidin-1-yl]-benzamide ;

(±)-3-[7-[3-(2-Dimethylamino-ethyl)-phenylamino]-3-(4-methoxy-phenyl)-4-methyl-2-oxo-3,4-dihydro-2H-pyrimido[4,5-d]pyrimidin-1-yl]-benzamide ; and

(±)-3-(3-(4-Methoxy-phenyl)-4-methyl-7-{3-[2-(4-methyl-piperazin-1-yl)-ethyl]-phenylamino}-2-oxo-3,4-dihydro-2H-pyrimido[4,5-d]pyrimidin-1-yl)-benzamide .

13. The compound

(+)-3-(2-Bromo-phenyl)-7-[4-(2-diethylamino-ethoxy)-phenylamino]-1,4-dimethyl-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one.

14. The compound

(-)-3-(2-Bromo-phenyl)-7-[4-(2-diethylamino-ethoxy)-phenylamino]-1,4-dimethyl-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one.

15. The compound

(±)-3-(2-Bromo-phenyl)-7-[4-(2-diethylamino-ethoxy)-phenylamino]-1,4-dimethyl-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one.

16. (Currently Amended) A ~~pharmaceutical~~ composition comprising a therapeutically effective amount of a compound of claim 1 and pharmaceutically acceptable carrier or excipient.

17. (Currently amended) A method for treating <u>breast or colon</u> cancer comprising <u>the administration of</u> ~~administering to a patient in need of such treatment~~ a therapeutically effective amound of a compound of claim 1.

Claims 18 - 20. (Canceled)

21. A compound selected from the group:

(±)-Acetic acid 2-{3-[8-(3-cyano-phenyl)-6-(4-methoxy-phenyl)-5-methyl-7-oxo-5,6,7,8-tetrahydro-pyrimido[4,5-d]pyrimidin-2-ylamino]-phenyl}-ethyl ester and

(±)-Methanesulfonic acid (2-{3-[8-(3-cyano-phenyl)-6-(4-methoxy-phenyl)-5-methyl-7-oxo-5,6,7,8-tetrahydro-pyrimido[4,5-d]pyrimidin-2-ylamino]-phenyl}-ethyl)-ester,